A team of researchers from Kaunas University of Technology and Lithuanian University of Health Sciences proposed a non-invasive method for detection of melanoma. A patented computer-aided diagnostic system developed by Lithuanian scientists proved to be more than 90% accurate in detecting malignancy in diagnostic images of skin lesions acquired from 100 patients.
In Europe, melanoma is the fifth most common type of cancer and is the major cause of death from skin cancer. Northern Europe displays the largest age-standardised rate mortality of 3.8 per 10,000 in the region, with an incidence of 23.4.
Excision of a primary tumour remains essential in diagnosing melanoma, and the decision for the operation is generally based on the dermatoscopic evaluation of the lesion. However, the accuracy of melanoma clinical diagnosis is only at 65% and strongly relies on the experience of the physician-dermatologist carrying out the analysis.
“The novelty of our method is that it combines diagnostic information obtained from different non-invasive imaging technologies such as optical spectrophotometry and ultrasound. Based on the results of our research, we can confirm that the developed automated system can complement the non-invasive diagnostic methods currently applied in the medical practice by efficiently differentiating melanoma from a melanocytic mole”, says Professor Renaldas Raišutis, head of the team behind the research at Kaunas University of Technology.
In the study, carried out by the researchers of two Lithuanian universities, diagnostic images of skin lesions acquired from 100 different patients were evaluated. By comparing and analysing complex data on skin tumours recorded by different techniques, the researchers were able to develop a novel diagnostic system, differentiating melanoma from a benign nevus with accuracy higher than 90%.
“An efficient diagnosis of an early-stage malignant skin tumour could save critical time: more patients could be examined and more of them could be saved”, says Prof Raišutis.
According to Prof Raišutis, the novel diagnostic system is firstly aimed at medical professionals; he estimates that the price of the final product might be affordable even for smaller medical institutions. However, the team is also thinking about the solutions for individual use at home.
Following the research, the prototype of the technology was developed, and the clinical research is being carried out complying with the requirements of the protocol for the clinical research confirmed by the regional bioethics committee.
The invention was patented in Lithuania (Patent No. LT6670B) and the patent applications filed for Patent Cooperation Treaty and the United States Patent and Trademark Office.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Early detection of lung cancer can help save lives, health experts say
Lung cancer is the leading cause of cancer deaths in the country. According to the American Cancer Society, More than 236,000 Americans will be diagnosed with lung cancer this year, and more than half ...
- Early detection screening awareness focus of World Lung Cancer Day
A new American Lung Association Survey shows nearly 70% of Americans are not aware of early detection lung cancer screening for people at high risk.
- American Lung Association urges early detection lung cancer screenings for people at high risk
A new American Lung Association survey shows nearly 70 percent of Americans are not aware of early detection lung cancer screening for people at high risk. Guidelines from the U.S. Preventive Services ...
- Medical Minute: World Lung Cancer Day
Monday, August 1 is World Lung Cancer Day, a day to raise awareness about the leading cause of cancer deaths in the U.S., according to the American Lung Association.
- World Lung Cancer Day: a call to action
Monday, August 1, is World Lung Cancer Day, a day to raise awareness about the leading cause of cancer deaths in the U.S., according to the American Lung Association.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Better observed vs. predicted survival rate found for class 2 uveal melanoma tumors
In patients with class 2 uveal melanoma tumors, predicted metastasis-free survival by a gene expression profile test was shown to be worse than that observed in a cohort study and worse than that ...
- Margin Size Associated With Risk of Local Recurrence From Melanoma In Situ
This new study, conducted among persons living with melanoma in situ, investigated the possibility of identifying clinicopathological predictors of local recurrence.
- AI and Dermatologists Similarly Judge Melanoma Thickness
Both readers and artificial intelligence predict melanoma thickness with fair to moderate accuracy using dermoscopy images, according to a study published online July 16 in the Journal of the European ...
- DecisionDx®-Melanoma Ordered More Than 100,000 Times for Patients Diagnosed with Cutaneous Melanoma
(Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a significant milestone for the Company’s DecisionDx®-Melanoma gene expression profile test ...
- Dr Vernon Sondak on BRAF Mutations in Metastatic Melanoma
In this interview, Vernon Sondak, MD, the chair of the Department of Cutaneous Oncology at the H. Lee Moffitt Cancer Center and Research Institute in Florida, explains the latest approach to treating ...